A. S. Hudz, G. E. Zakharevich


Summary. Research objective: clarifi cation of VEGFA role in advancing of the diabetic retinopathy (DR) and development of non-proliferative and proliferative DR. 302 patients were included: 1st group (n=76) – patients with DR without visible changes on the eye fundus; 2nd group (n=64) – patients with non-proliferative and 3-rd group (n=64) – patients with proliferative DR (DPR). The control group included 98 patients without diabetes mellitus. VEGFA measurement was carried out in aqueos humor by enzyme immunoassay method (eBioscience Thermo Fisher Sci.; USA). Results showed that patients with DPR were younger than other patients for 5–9 years, had diabetes duration longer (8–15 years), and almost all of themwere  decompensated (93,4 % of patients). The worst visual acuity was also noted in DPR patients (in control group the median of the maximum visual acuity with correction was 1,0, in the 1st and 2nd groups, respectively, 0,8 and 0,7, and in the 3rd group – 0,2 ). The maximum value of a median of intraocular pressure (18 mm hg) was also noted in DPR group. In this group the medians of indicators of the central retina thickness and volume of the retina were increased the most (by 1,3–1,4 times; p<0,01). The VEGFA level in aqueos humor exceeded control in the 1st group by 5,5 times, in the 2nd – by 6,0 times and in the 3rd – by 9,5 times (p<0,01). Such an increase (by 5–6 times) of VEGFA contents is a pathogenetic factor of non-proliferative DR development, and its further augmentation (by 9,5 times) causes DPR development. Respectively, in our research this fact coincides with more serious implications of disturbances of carbohydrate metabolism, visual acuity and ophthalmologic indicators in patients with DPR, which develops at younger age.


type II diabetes, diabetic retinopathy, progression, risk factors


Власенко М. В. Цукровий діабет: діагностика і моніторинг / М. В. Власенко // Ліки України. – 2013. – № 9–10. – С. 17–18.

Коненков В. И. Ангиогенез при пролиферативной диабетической ретинопатии: перспективы анти-VEGF-терапии / В. И. Коненков, В. В. Климонтов, В. В. Черных, Н. В. Тян // Офтальмохирургия. – 2013. – № 4. – С. 111–115.

Паньків В. І. Симпозіум № 162 «Цукровий діабет: діагностичні критерії, етіологія і патогенез» / В. І. Паньків // Міжнародний ендокринологічний журнал. – 2013. – № 8. – С. 53–64.

Abouammoh M. A. Ranibizumab injection for diabetic macular edema: meta-analysis of systemic safety and systematic review / M. A. Abouammoh // Can. j. ophthalmol. – 2013. – Vol. 48, № 4. – P. 317–323.

Izuta H. Proliferative diabetic retinopathy and relations among antioxidant activity, oxidative stress and VEGF in the vitreous body / H. Izuta, N. Matsunaga, M. Shimazawa [et al.] // Mol Vis. – 2010. – Vol. 16. – P. 130–136.

Sayin N. Ocular complications of diabetes mellitus / N. Sayin, N. Kara, G. Pekel // World J Diabetes. – 2015. – Vol. 6, № 1. – P. 92–108.

Scanlon P. H. Epidemiological issues in diabetic retinopathy / P. H. Scanlon, S. J. Aldington, I. M. Stratton // Middle East Afr. J. Ophthalmol. – 2013. – Vol. 20, № 4. – P. 293–300.

Bonnefond A. What is the contribution of two genetic variants regulating VEGF levels to type 2 diabetes risk and to microvascular complications? / A. Bonnefond, P. J. Saulnier, M. G. Stathopoulou [et al.] //PloS one. – 2013. – Vol. 8, № 2. – e55921.


  • There are currently no refbacks.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.


© "Publishing House "Zaslavsky", 1997-2019


   Seo анализ сайта